tiprankstipranks
Trending News
More News >
Taysha Gene Therapies, Inc. (TSHA)
:TSHA
US Market
Advertisement

Taysha Gene Therapies (TSHA) AI Stock Analysis

Compare
1,109 Followers

Top Page

TSHA

Taysha Gene Therapies

(NASDAQ:TSHA)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 4o)
Rating:53Neutral
Price Target:
$3.50
▲(11.11% Upside)
Taysha Gene Therapies' overall stock score reflects significant financial challenges, balanced by strong clinical progress and positive technical momentum. The company's extended cash runway and regulatory achievements are promising, but ongoing losses and valuation concerns weigh on the score.
Positive Factors
Regulatory Alignment
Regulatory alignment with major health authorities enhances the company's ability to advance its gene therapy programs, potentially accelerating time to market and improving patient access to innovative treatments.
Financial Strength
The substantial financial runway into 2028 provides Taysha with the resources needed to continue R&D and clinical trials without immediate financial pressure, supporting long-term strategic initiatives.
Promising Clinical Data
Strong clinical trial results with a 100% response rate support the efficacy of Taysha's gene therapy, potentially leading to successful commercialization and improved patient outcomes.
Negative Factors
Increased Expenses
Rising R&D expenses, while necessary for growth, can strain financial resources and impact profitability, posing a challenge to maintaining financial health in the long term.
Net Loss Increase
Increasing net losses highlight ongoing financial challenges, which may hinder the company's ability to achieve profitability and require careful management to sustain operations.
Negative Cash Flow
Negative cash flow from operations suggests the company is not generating sufficient cash internally, potentially leading to reliance on external financing to fund its activities.

Taysha Gene Therapies (TSHA) vs. SPDR S&P 500 ETF (SPY)

Taysha Gene Therapies Business Overview & Revenue Model

Company DescriptionTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
How the Company Makes MoneyTaysha Gene Therapies primarily generates revenue through a combination of product sales, partnerships, and collaborations in the biotechnology sector. The company is focused on advancing its gene therapy candidates through clinical trials and subsequently commercializing these products upon regulatory approval. Key revenue streams include milestone payments from partnerships with larger pharmaceutical companies that may involve co-development or licensing of Taysha's gene therapies. Additionally, Taysha may receive royalties on sales of approved therapies, further contributing to its earnings. The company also benefits from grants and funding aimed at supporting research and development in gene therapies, which can provide crucial financial backing as it progresses through various stages of product development.

Taysha Gene Therapies Earnings Call Summary

Earnings Call Date:Aug 12, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Positive
The earnings call indicates strong progress in clinical trials, financial stability, and regulatory alignment, suggesting a positive trajectory for Taysha Gene Therapy. However, increased expenses and net loss present financial challenges.
Q2-2025 Updates
Positive Updates
FDA and Health Canada Alignment
Taysha Gene Therapy has obtained alignment with the FDA and Health Canada to proceed with initiating the REVEAL pivotal trial for TSHA-102, with site activation officially commenced.
Financial Strength
The company completed a public follow-on offering resulting in gross proceeds of $230 million, extending their cash runway into 2028.
Promising Clinical Data
All patients treated in Part A of the REVEAL trials gained or regained developmental milestones, corresponding to a 100% response rate for the pivotal trial’s primary endpoint.
Regulatory Progress
Commencement of site activation for pivotal trial with anticipated patient enrollment in Q4 2025.
Negative Updates
Increased Expenses
Research and development expenses increased to $20.1 million, driven by manufacturing initiatives and higher compensation expenses.
Net Loss Increase
The net loss for the quarter ended June 30, 2025, was $26.9 million compared to a net loss of $20.9 million for the same period in 2024.
Company Guidance
During Taysha Gene Therapy's second quarter 2025 earnings call, the company highlighted several key metrics and milestones for their TSHA-102 program aimed at treating Rett syndrome. Notably, the company achieved alignment with the FDA and Health Canada, enabling the initiation of their REVEAL pivotal trial. They plan to begin patient enrollment in the fourth quarter of 2025. The program's development is supported by promising clinical data, with a 100% response rate at the primary endpoint in the REVEAL Part A trials, demonstrating developmental milestone gains in all ten patients treated. Financially, Taysha reported a net loss of $26.9 million for the quarter, with $312.8 million in cash and equivalents, bolstered by a $230 million follow-on financing. The company expects this funding to extend their cash runway into 2028, supporting their ongoing efforts to bring TSHA-102 to market for the estimated 15,000 to 20,000 patients affected by Rett syndrome across the U.S., Europe, and the U.K.

Taysha Gene Therapies Financial Statement Overview

Summary
Taysha Gene Therapies is facing financial challenges with ongoing losses and declining revenues. The balance sheet shows moderate leverage, but low equity levels signal financial instability. Negative cash flows further highlight liquidity constraints, posing challenges for sustainable growth and profitability.
Income Statement
30
Negative
Taysha Gene Therapies shows persistently negative net income and declining revenues, leading to weak profitability metrics. The company exhibits low EBIT and EBITDA margins and a negative revenue growth trajectory, indicating challenges in achieving operational efficiency and revenue generation.
Balance Sheet
40
Negative
The balance sheet reflects a moderate debt-to-equity ratio and a declining equity base, suggesting financial strain. The equity ratio indicates limited shareholder equity relative to assets. The company's leverage and low equity position present financial stability risks.
Cash Flow
35
Negative
Cash flows are negative, driven by substantial operating losses. The cash flow to net income ratios are unfavorable, pointing to cash management challenges. Limited free cash flow growth indicates potential liquidity issues, despite consistent financing inflows.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue8.10M8.33M15.45M2.50M0.000.00
Gross Profit7.82M8.33M15.45M2.50M-492.00K-9.00K
EBITDA-91.64M-87.95M-105.20M-159.73M-172.78M-59.97M
Net Income-92.72M-89.30M-111.57M-166.01M-175.46M-43.00M
Balance Sheet
Total Assets333.33M160.36M172.73M126.28M213.96M258.88M
Cash, Cash Equivalents and Short-Term Investments312.76M139.04M143.94M87.88M149.10M251.25M
Total Debt16.81M63.18M61.11M59.93M63.09M0.00
Total Liabilities84.60M88.84M97.79M125.33M118.57M7.58M
Stockholders Equity248.73M71.53M74.94M949.00K95.38M251.30M
Cash Flow
Free Cash Flow-82.54M-81.60M-80.39M-113.26M-138.60M-39.81M
Operating Cash Flow-82.13M-81.22M-73.02M-88.39M-117.04M-30.73M
Investing Cash Flow-331.00K-363.00K-7.35M-24.93M-21.55M-9.08M
Financing Cash Flow222.47M76.68M136.39M52.10M39.08M291.06M

Taysha Gene Therapies Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.15
Price Trends
50DMA
2.88
Positive
100DMA
2.71
Positive
200DMA
2.21
Positive
Market Momentum
MACD
0.03
Positive
RSI
53.27
Neutral
STOCH
63.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSHA, the sentiment is Positive. The current price of 3.15 is above the 20-day moving average (MA) of 3.04, above the 50-day MA of 2.88, and above the 200-day MA of 2.21, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 53.27 is Neutral, neither overbought nor oversold. The STOCH value of 63.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSHA.

Taysha Gene Therapies Risk Analysis

Taysha Gene Therapies disclosed 83 risk factors in its most recent earnings report. Taysha Gene Therapies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Taysha Gene Therapies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$859.30M-51.86%-37.09%58.96%
52
Neutral
408.85M19.092990.57%
46
Neutral
573.10M-4.266.82%
39
Underperform
261.84M-0.181138.25%38.82%-645.78%
38
Underperform
675.51M-7.52
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSHA
Taysha Gene Therapies
3.06
0.96
45.71%
RNAC
Cartesian Therapeutics
9.46
-7.90
-45.51%
OLMA
Olema Pharmaceuticals
8.19
-4.03
-32.98%
GLUE
Monte Rosa Therapeutics
6.55
1.19
22.20%
TSVT
2seventy bio
5.00
0.24
5.04%
MBX
MBX Biosciences, Inc.
17.33
-7.16
-29.24%

Taysha Gene Therapies Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Taysha Gene Therapies Approves Share Increase Amendment
Neutral
Jun 3, 2025

On June 2, 2025, Taysha Gene Therapies, Inc. held its annual meeting of stockholders where an amendment to increase the authorized number of shares of common stock from 400,000,000 to 700,000,000 was approved. Additionally, two directors were elected, and Deloitte & Touche LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions reflect the company’s strategic focus on expanding its capital structure and solidifying its governance framework.

Private Placements and Financing
Taysha Gene Therapies Announces Major Stock Offering
Neutral
May 29, 2025

On May 28, 2025, Taysha Gene Therapies announced an underwriting agreement to sell 46,868,687 shares of common stock and pre-funded warrants for 25,858,586 shares in a public offering, expecting to raise approximately $187.4 million. The offering, managed by Jefferies, BofA Securities, Piper Sandler, and Barclays, aims to fund the company’s operations and capital expenditures into 2028, with the closing expected on May 30, 2025.

Product-Related AnnouncementsBusiness Operations and Strategy
Taysha Gene Therapies Announces Pivotal Trial Design for TSHA-102
Positive
May 28, 2025

On May 28, 2025, Taysha Gene Therapies announced the design details for the pivotal Part B trial of TSHA-102 in Rett syndrome, following positive clinical data from Part A of the REVEAL trials. The trial, supported by the FDA, aims to assess developmental milestone gains in patients aged six and above, with the company planning to initiate the pivotal program in the third quarter of 2025. Additionally, Taysha suspended its ATM Prospectus related to $100 million of common stock but maintained the Sales Agreement in effect.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 05, 2025